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More than 20 years ago the amyloid precursor protein (APP) was identified as the
precursor protein of the Aβ peptide, the main component of senile plaques in brains
affected by Alzheimer’s disease (AD). The pathophysiology of AD, characterized by a
massive loss of synapses, cognitive decline, and behavioral changes was in principle
attributed to the accumulation of Aβ. Within the last decades, much effort has gone
into understanding the molecular basis of the progression of AD. However, little is
known about the actual physiological function of APPs. Allocating APP to the proteome
of the structurally and functionally dynamic presynaptic active zone (PAZ) highlights
APP as a hitherto unknown player within the setting of the presynapse. The molecular
array of presynaptic nanomachines comprising the life cycle of synaptic vesicles, exo-
and endocytosis, cytoskeletal rearrangements, and mitochondrial activity provides a
balance between structural and functional maintenance and diversity. The generation
of genetically designed mouse models further deciphered APP as an essential player in
synapse formation and plasticity. Deletion of APP causes an age-dependent phenotype:
while younger mice revealed almost no physiological impairments, this condition was
changed in the elderly mice. Interestingly, the proteomic composition of neurotransmitter
release sites already revealed substantial changes at young age. These changes point
to a network that incorporates APP into a cluster of nanomachines. Currently, the
underlying mechanism of how APP acts within these machines is still elusive. Within the
scope of this review, we shall construct a network of APP interaction partners within the
PAZ. Furthermore, we intend to outline how deletion of APP affects this network during
space and time leading to impairments in learning and memory. These alterations may
provide a molecular link to the pathogenesis of AD and the physiological function of APP
in the central nervous system.
Keywords: Alzheimer’s disease, amyloid precursor protein, calcium homeostasis, mitochondria, presynaptic
active zone
Abbreviations: Aβ, amyloid beta; AD, Alzheimer’s disease; APLP2, amyloid precursor like protein 2; APP, amyloid
precursor protein; CAST, CAZ-associated structural protein; CAZ, cytomatrix of the active zone; CoQ, coenzyme Q;
CoQH2, reduced CoQ; LTCC, L-type calcium channels; Munc, mammalian uncoordinated; NSF, N-ethylmaleimide
sensitive fusion protein; PPI, protein-protein interaction network; PAZ, presynaptic active zone; RIM, Rab-interacting
molecule; RIM-BP, rab-interacting binding protein; ROS, reactive oxygen species; SNARE, soluble NSF-attachment receptor
proteins; SNAP25, synaptosomal associated protein 25; VAMP2, vesicle associated membrane protein2/synaptobrevin2;
VDCC, voltage dependent calcium channels.
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APP—NETWORKING WITHIN
PRESYNAPTIC NANOMACHINES
(INTRODUCTION)
The idea of nanotechnology helping to redesign everything
at the atomic level goes back to the American engineer Eric
Drexler (Drexler, 1987). More than 20 years ago, he published
his still controversially discussed book ‘‘Engines of Creation’’
almost at the same time as scientists discovered a protein
that fits perfectly in the conceptual idea of nanotechnology.
The protein, named amyloid precursor protein (APP), was
originally discovered as precursor of amyloid beta (Aβ), the
main component of senile plaques and hallmark of Alzheimer’s
disease (AD; Glenner and Wong, 1984; Kang et al., 1987).
Nanomachines are autonomic miniature machines that can
work on their own. However, under distinct circumstances
they demand on helping hands called assemblers. The vision
of autonomic assemblers performing every physical and
chemical application, that can have a lasting positive but also
negative effect on people’s life, would change the way of
scientific thinking in a sustainable manner (Drexler, 1987).
If we transpose this image to APP, our protein of interest,
we can observe similar properties in regulating synaptic
development and degeneration. Enzymatic processing, ligand-
binding, and dimerization of APP can induce the development
andmaintenance of neuronal circuits but also their degeneration.
Aβ, mainly associated with the pathogenesis of AD can also
protect neurons from neurotoxicity. Furthermore, elimination of
synapses initiated by Aβ already occurs during the development
of neuronal circuits (Kamenetz et al., 2003; Hsieh et al., 2006;
Abrahamsson et al., 2007; Wasling et al., 2009). This sensitive
balance between physiological benefit and pathophysiological
hallmarks is reflected by many processes taking place within a
synapse.
Regarding the synapse at the macroscopic level, there
are two highly complex nanomachines named pre- and
postsynaptic terminal. However, on a microscopic level,
both termini can be further subdivided into more restricted
nanomachines with specific tasks and assemblers that regulate
and control their functions (e. g., neurotransmitter release, signal
transduction and reorganization). Within this review, we will
focus on the presynaptic terminal with special emphasis on the
neurotransmitter release site and its constituent the APP.
Allocating APP to the proteome of the structurally and
functionally dynamic presynaptic active zone (PAZ) identified
APP as a hitherto unknown player within the setting of
the presynaptic nanomachines (Laßek et al., 2013). The
molecular array of presynaptic nanomachines comprising the
life cycle of synaptic vesicles, exo- and endocytosis, cytoskeletal
rearrangements, and mitochondrial activity provides a balance
between structural and functional maintenance and diversity
(Südhof, 2012; Laßek et al., 2014b, 2015; Weingarten et al.,
2014, 2015). The generation of genetically designed mouse
models further deciphered APP as an essential player in
synapse formation and plasticity (Heber et al., 2000; Wang
et al., 2005, 2009b; Ring et al., 2007; Weyer et al., 2011;
Hick et al., 2015). Deletion of APP causes an age-dependent
phenotype: while younger mice revealed almost no physiological
impairments, this condition was changed in the elderly mice
(Phinney et al., 1999; Priller et al., 2006; Ring et al., 2007).
Interestingly, substantial changes of the proteomic composition
of neurotransmitter release sites are already detectable in
younger mice (Laßek et al., 2014a). Since APP plays an
essential role during the development of neuronal circuits, it
was suggested that the amyloid precursor like protein APLP2
compensates for the loss of APP (Weyer et al., 2011; Hick
et al., 2015). Therefore, it is tempting to speculate that APP
itself can act as a nanomachine with its assembler APLP2.
The deletion of the assembler does not account for a severe
phenotype. However, at the protein level the abundance of the
nanomachine APP becomes increased (Laßek et al., 2014a).
Reversely, deletion of the APP can only be compensated by the
assembler up to a certain time. Like an electronic device that
still works after removing from its charger until the battery has
discharged.
Within the presynapse many clusters of nanomachines
could be identified. These machines are involved in numerous
physiological processes that have to be regulated, coordinated
and modified. In the following sections APP will be embedded
into selected presynaptic clusters of nanomachines (Figure 1).
APP AND SYNAPTIC VESICLE
EXOCYTOSIS—ASSEMBLERS AT WORK
Synaptic transmission requires a coordinated network decoding
an action potential into a chemical signal at the PAZ. Therefore,
consecutive steps including the recruitment of Ca2+-channels,
exocytosis and endocytosis are processed by nanomachines
and its assemblers. The recruitment of Ca2+-channels as
nanomachines is performed by a protein complex comprising
the assemblers RIM, Munc13, RIM-BP, α-liprin and CAST-
proteins. These assemblers belong to the so called ‘‘active
zone key proteins’’, also including bassoon, ELKS and CASK
proteins. APP as an assembler is functionally integrated within
this conserved network of active zone key players (Figure 1).
The interaction with bassoon regulates the recruitment of ERC
protein 2 (ELKS), RIM, and Munc13 that are essential for
docking and priming of synaptic vesicles (Südhof and Rizo, 2011;
Südhof, 2012, 2013b).
Exocytosis of synaptic vesicles is mediated by SNARE-
complex formation whereby the integral synaptic vesicle protein
VAMP2 forms a complex with the presynaptic plasmamembrane
proteins syntaxin-1 and SNAP25. The SNARE complex is a
nanomachine that is characterized by a quadruple α-helix
bundle with VAMP2 and syntaxin-1 contributing one α-helix
each and SNAP25 contributing two α-helixes. Before the
SNARE complex can be formed, syntaxin-1 has to change its
conformation from closed (due to binding to the assembler
Munc-18); to open (supported by the assembler Munc13).
In the open conformation, Munc-18 is still associated with
syntaxin-1 supporting the interaction between SNARE motifs
derived from syntaxin-1 and SNAP25 (Südhof, 2013b). The
resulting donor-complex further binds to VAMP2 assembling
to a Munc-18-SNARE complex, with Munc-18 being supposed
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FIGURE 1 | Conceptual circuit integrating nanomachines and assemblers within the presynaptic active zone (PAZ). APP is embedded into the circuit of
nanomachines within the PAZ. It can act within different physiological processes at the presynaptic terminal including synaptic vesicle exocytosis, Ca2+-homeostasis
and mitochondrial function. A well balanced proportion between the machines and their assemblers is the prerequisite for the development and maintenance of the
neuronal circuits. Nanomachines are visualized as green squares; assemblers as yellow circles. APP can act as a nanomachine and as an assembler—the square is
therefore colored in green and yellow. Black arrows represent the interactions between individual nanomachines. Connecting lines are highlighted in blue. Depicted
are: α-subunit of voltage dependent Ca2+-channels (VDCC); exocytosis of SV, with APP embedded into the presynaptic plasma membrane; illustration of APP;
mitochondria. Abbreviations: Aβ, amyloid-beta; Ca2+, calcium ion; PAZ, presynaptic active zone; ROS, reactive oxygen species.
to mediate interactions between the four-helix bundle and
the plasma membrane necessary for membrane fusion (Deák
et al., 2009). Furthermore, Munc-18 does not detach during
the SNARE complex assembly/disassembly cycle, emphasizing
its essential role in exocytosis (Südhof, 2013a). APP plays
a crucial role in synaptic vesicle exocytosis and further
emphasizes the compensatory role of APLP2 in APP-KO
mice. Moreover, the interaction of APP with presynaptic
proteins involved in the regulation of exocytosis and the
putative function in tuning this process is important to
unravel the physiology of APP within the CNS (Fanutza et al.,
2015).
Within the molecular nanomachinery of SNARE-complex
formation, α-synuclein is an indispensable assembler. The
role of α-synuclein during SNARE complex formation is
the implementation of VAMP2 into the SNARE donor
complex (Burré et al., 2010). Therefore, the interaction
between synaptophysin and VAMP2 has to be repealed
before complete vesicle fusion can take place (Valtorta
et al., 2004) putatively mediated by α-synuclein. At protein
level, deletion of α-synuclein does not alter the abundance
of SNARE proteins, but diminishes the ability of SNARE
complex formation. In terms of nanotechnology, loss of the
assembler accounts for severe impairments of the nanomachine.
Interestingly, α-synuclein and APP are both assemblers within
this highly complex SNARE-machinery, but they act differently.
While α-synuclein mediates SNARE-complex formation, APP
might execute a regulatory function during docking and
priming of synaptic vesicles. After neurotransmitter release, the
assembler NSF mediates the hydrolysis of ATP and triggers
the disassembling of the SNARE nanomachine (Littleton et al.,
2001).
APP AND CALCIUM—PARTNERS IN
CRIME
During the mid-1980’s when APP was discovered as precursor
protein of Aβ, another crucial player within the pathogenesis
of AD was identified—calcium (Khachaturian, 1987; Landfield,
1987; Landfield et al., 1989; Small et al., 2009). APP and
calcium share some interesting features that interconnect them as
partners in crime.Moreover, they fit perfectly into the conceptual
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idea of nanomachines and assemblers. They can operate
as neurotrophic assemblers supporting proper physiological
function of the presynaptic terminal, but they also trigger
neurodegeneration.
Ca2+-influx through voltage-dependent channels within the
presynaptic terminal is essential for neurotransmitter release
(Mattson, 2007). The complex protein machinery (Südhof,
2012) that ensures the presence of voltage dependent calcium
channels (VDCC) at active zones after the arrival of action
potentials comprises a varying set of assemblers (Figure 1). These
assemblers have to act in a consecutive manner to provide a
rapid increase in intracellular Ca2+. However, the elevation of
intracellular Ca2+-levels is only transiently and residual amounts
of Ca2+ have to be removed quickly to avoid adverse effects on
neurons (Mattson, 2007; Bezprozvanny andMattson, 2008; Small
et al., 2009).
Disruption of Ca2+-homeostasis can account for neuronal
dysfunction and neurodegeneration. In this context, Aβ
oligomers have been discussed to induce increase intracellular
Ca2+-levels, thereby altering synaptic signaling and changing the
activity of neighboring neurons. Since neuronal activity is under
the control of a neuronal network, systematic failure within
this network account for alterations within the network circuit
(Small, 2008; Small et al., 2009). The vicious cycle describing
the maintenance of the neuronal signaling within the network is
based on synaptic compensation (scaling). Aβ oligomers induces
elevated Ca2+-influx, that accounts for synaptic dysfunction,
followed by synaptic scaling and consequently increased
excitability with in turn leads to elevated intracellular Ca2+. At
the end, healthy neurons degenerate due to Ca2+-dysregulation
and synaptic dysfunction (Small, 2008). Interestingly, the
abundance of VDCC, in particular L-type calcium channels
(LTCC), is also increased during aging and in AD (Thibault and
Landfield, 1996; Thibault et al., 2001).
APP is involved in the recruitment of VDCC (Figure 1)
and the regulation of their abundance at hippocampal
neurotransmitter release sites. The hippocampus, a brain
region of interest regarding learning and memory consolidation,
is highly susceptible for excitotoxicity and neurodegeneration.
Both can be induced and triggered by long-lasting elevated
intracellular Ca2+-levels. Moreover, diminished endocytosis
of VDCC in the absence of APP accounts for a dysregulation
of the balance between inhibitory and excitatory neurons.
GABAergic hippocampal neurons revealed increased activity
due to an increased abundance of VDCC at presynaptic
terminals (Yang et al., 2009). Moreover, LTP deficits in APP
double and single mutant mice were rescued by application
of GABAA receptor inhibitor picrotoxin (Fitzjohn et al.,
2000; Weyer et al., 2011). This molecular interpretation of
changes in calcium homeostasis and subsequent alterations
in synaptic plasticity was manifested by electrophysiological
network analysis. In this context, it was proposed that APP
deletion induces an altered neuronal excitation-inhibition
ratio (Korte et al., 2012). Within the hippocampus memory
formation is based on a variety of synchronized network
oscillations that are regularly synchronized between the
CA1 and CA3 region (Korte et al., 2012). As inhibitory
interneurons play an essential role in synchronizing these
oscillations they can affect a large population of pyramidal
neurons, inhibit specific input pathways and guarantee
for a high background-to-noise ratio (Mann and Paulsen,
2007). This might explain the reported alteration in the
excitation-inhibition ratio (Korte et al., 2012). Similarly,
alterations during the pathogenesis of AD such as changes
in personality, sleep disturbance and changes in awareness
could be traced back to a dysregulation of the glutamate-
GABA metabolism (Robinson, 2000; Doert et al., 2015). GABA
can be produced by the so called GABA shunt, a bypass
mechanism that skips the intra-mitochondrial α-ketoglutarate-
dehydrogenase (Mamelak, 2012). This mechanism becomes
operative when the metabolism of glutamate is enhanced
probably due to reduced glutamine synthase activity. Elevated
GABA levels in transgenic APP mutant mice, carrying the
Swedish and London mutation for APP, (Doert et al., 2015)
reflect a situation for the glutamate-GABA ratio similar to
that observed for APP knockout mice (Weyer et al., 2011;
Korte et al., 2012). Both phenotypes indicate a critical role
of APP in memory formation and consolidation as well as
behavioral aspects that are severely affected in in the respective
mutants and in AD patients (Ring et al., 2007; Doert et al.,
2015).
APP AND
MITOCHONDRIA—NANOMACHINES AND
ASSEMBLERS TWO-IN-ONE
Within the presynaptic terminal, mitochondria are essential
nanomachines, providing energy supply and calcium buffering
for a large variety of physiological functions. However,
mitochondrial dysfunctions are in focus of playing an important
role in the pathology of AD.
Considering the pros and cons of nanomachines at work
as described above for APP and Aβ, we can outline a similar
feature for mitochondria that can be physiological but also
pathophysiological. Both subjects can function as nanomachine
and assembler depending on the perspective. Mitochondria
produce reactive oxygen species (ROS) that are assemblers
(Figure 1). The amount of ROS is in general regulated by oxygen
donor concentration and enzymes of the electron transport
chain. Oxygen level and donor concentration trigger the amount
of ROS in a linear manner. ROS, produced as superoxide anion
(O•−2 ), hydrogen peroxide (H2O2) and hydroxyl radical (•OH)
at complex I and complex III of the electron transport chain
need to be critically regulated (Leuner et al., 2012a). Within
the mitochondrial matrix ROS production depends critically on
the proton gradient (∆p), the NADH/NAD+ and CoQH2/CoQ
ratios and the local O2 concentration. Superoxide anions are
mainly produced at complex I. Under physiological conditions,
the production of O•−2 at complex III is insignificant as compared
to the production rates by complex I (Murphy, 2009). Therefore,
the outcome ‘‘oxidative stress’’ is on the one hand initiated by
the mitochondria themselves, but at the same time affects its
producer as first objective (Harper et al., 2004; Korge et al., 2008;
Poyton et al., 2009; Müller et al., 2010). Besides ROS, dysfunction
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of the entire respiratory system, associated by a decrease in
mitochondrial membrane potential and reduced levels of ATP,
account for impairments in mitochondrial function and trigger
the early onset of neurodegeneration (Rhein et al., 2009; Wang
et al., 2009a; Leuner et al., 2012a). APP and Aβ have been directly
associated with mitochondrial function (Leuner et al., 2010,
2012a; Eckert et al., 2012) and in this context, it would be of great
interest to study the effect of APP deletion on mitochondrial
function at neurotransmitter release sites.
Neuronal communication is based on reliable functioning of
synaptic vesicle exo- and endocytosis. Already slight alterations
can disrupt this procedure. In terms of our topic nanomachines
and its assemblers, APP and mitochondria both provide a clear
picture of a classical nanomachine and their proteolytic and/or
metabolic products are assemblers (Figure 1). The balance
between physiological benefit and pathophysiological effect is
fragile. Similar to the sensitive Ca2+-homeostasis, imbalance
between ROS and/or Aβ causes mitochondrial dysfunction,
membrane protein and membrane lipid modifications (Eckert
et al., 2003). Generation of ROS occurs along the electron
transport chain at complex I and complex III. Recently, Leuner
et al. (2012b) identified complex I in conjunction with elevated
ROS levels as starting point for mitochondrial dysfunctions and
onset of the amyloidogenic cascade in AD. ROS can trigger
the production of Aβ via enhancing the enzymatic activity of
BACE1 and γ-secretase. Interestingly, Aβ oligomers, as well as
Aβ fibrils can account for a decrease in mitochondrial membrane
potential and ATP levels. This phenotype has already been
detected in young transgenic mice prior to Aβ plaque formation
(Leuner et al., 2012a,b). Conversely, patients with mitochondrial
disorders like mitochondrial encephalopathy, lactic acidosis,
stroke-like episodes (MELAS) show cognitive impairments,
behavioral decline and AD-like plaque formation in the absence
of familiar AD evidence (Kaido et al., 1996).
It is widely accepted that changes in the interplay between
APP, Aβ and mitochondrial function are likely to correlate with
the onset of neurodegenerative diseases (Eckert et al., 2012;
Leuner et al., 2012a). Therefore, novel therapeutic strategies
that account for mitochondrial protection will be a promising
approach for AD treatment or prevention.
CONCLUSION AND OUTLOOK
Assemblers and nanomachines execute different but synergistic
functions within the PAZ. By communicating with individual
nanomachines, assemblers can control, navigate and trigger
physiological functions at the presynaptic terminal. Their
operations are based on an appropriate balance accompanied
by a variety of interaction- and combination possibilities (e. g.,
SNARE complex formation and Ca2+-signaling). If this balance
is dysregulated (e. g., increase in Aβ, ROS or calcium) and extend
physiological compensation mechanisms, pathophysiological
hallmarks (senile plaque formation, mitochondrial dysfunction
and neurodegeneration) will increase alarmingly.
One important player within this conceptual idea of
nanomachines is APP. Within the molecular array of
presynaptic nanomachines APP can equally act as an individual
nanomachine and assembler at once. It participates in crucial
steps like synaptic vesicle exocytosis and Ca2+-homeostasis
and has a major impact on proper mitochondrial function. All
these interplays depend on a highly coordinated proteinaceous
network. Unravelling how APP is embedded into individual
networks within neurotransmitter release sites and how
disturbances of the network may account for neurodegenerative
diseases needs to be addressed in future studies. Until now,
data derived from APP mutant mice (transgenic Alzheimer
mouse models or knockout mouse models) clearly point to an
essential role of APP in synaptic development, function and
plasticity. Changes at the behavioral level (e. g., cognitive decline,
impairments in LTP and memory) are characteristic for all APP
mutants and reveal a time depended development.
One possibility to address the question how APP is embedded
into the presynaptic nanomaschine is provided by bioinformatic
tools. The mathematical field of graph theory allows the
integration of all possible physical and functional relations
between proteins into a single model. This model is called
a protein-protein interaction network (PPI). By analyzing the
topological properties of such a PPI network the key molecular
players are identified and classified. These properties are used
to assign a topological role to a protein of interest. Whether
a protein is a highly connected hub or a less connected linker
between functional modules is indicated by its topological
properties in the PPI network and adds another layer of
information.
The pure topological model can be augmented with additional
information using, e.g., gene ontology terms and protein
localizations. The understanding of the functional composition
of the PAZ is facilitated by applying community detection
methods. These methods detect highly connected clusters of
proteins. The highly connected clusters of proteins are assumed
to act within the same biological processes. By analyzing the
biological functions represented by the individual communities
a global picture of interconnected functions and pathways arises.
If one takes all these individual approaches together, one
can design a molecular network of nanomachines and their
assemblers to gain further insights into the complex physiology
of presynaptic functions. Since APP affects this network during
space and time, leading to the development and the loss of
synapses, it is essential to understand how APP acts within
these individual networks. Currently, it is not known which
physiological function APP is executing but it is obvious
that APP plays an indispensable role in proper synaptic
function—including development and degeneration.
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